• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.

作者信息

Pol Jonathan, Kroemer Guido

机构信息

Equipe 11 labelisée par la Ligue Nationale contre le Cancer, INSERM U1138, Centre de Recherche des Cordeliers, Paris, 75006, France.

University of Paris Descartes, Sorbonne Paris Cité, Paris, 75006, France.

出版信息

Cell Res. 2018 May;28(5):501-502. doi: 10.1038/s41422-018-0031-9. Epub 2018 Mar 28.

DOI:10.1038/s41422-018-0031-9
PMID:29593340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5951874/
Abstract
摘要

相似文献

1
Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy.抗CTLA-4免疫疗法：分离毒性与疗效。
Cell Res. 2018 May;28(5):501-502. doi: 10.1038/s41422-018-0031-9. Epub 2018 Mar 28.
2
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.预防性 TNF 阻断可使 CTLA-4 和 PD-1 免疫治疗的疗效和毒性脱耦联。
Nature. 2019 May;569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1.
3
Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage .合成 DNA 编码单克隆抗体递送抗 CTLA-4 抗体诱导肿瘤缩小。
Cancer Res. 2018 Nov 15;78(22):6363-6370. doi: 10.1158/0008-5472.CAN-18-1429. Epub 2018 Oct 4.
4
Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.抗 CTLA-4 抗体联合冻存肿瘤裂解物致敏树突状细胞增强小鼠骨肉瘤抗肿瘤免疫
Oncol Rep. 2013 Mar;29(3):1001-6. doi: 10.3892/or.2013.2224. Epub 2013 Jan 4.
5
Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.经 GM-CSF 表达的神经胶质瘤细胞疫苗接种和 CTLA-4 阻断的序贯免疫疗法可有效治疗已建立的小鼠颅内肿瘤。
J Immunother. 2012 Jun;35(5):385-9. doi: 10.1097/CJI.0b013e3182562d59.
6
Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.抗细胞毒性T淋巴细胞相关蛋白4（Ctla-4）阻断疗法联合过继性T细胞转移可促进小鼠黑色素瘤免疫达到最佳状态。
J Immunother. 2015 Feb-Mar;38(2):54-61. doi: 10.1097/CJI.0000000000000064.
7
Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: In vitro and in vivo studies.采用脂质体包封抗体提高 CTLA-4 阻断抗体的肿瘤蓄积和治疗效果：体外和体内研究。
Nanomedicine. 2017 Nov;13(8):2671-2682. doi: 10.1016/j.nano.2017.08.010. Epub 2017 Aug 25.
8
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.通过CTLA-4阻断进行的抗癌免疫疗法依赖于肠道微生物群。
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.
9
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.使用免疫检查点抑制剂的癌症免疫疗法诱导的肝损伤的特征。
J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8.
10
CTLA-4: a moving target in immunotherapy.CTLA-4：免疫疗法中的一个移动靶标。
Blood. 2018 Jan 4;131(1):58-67. doi: 10.1182/blood-2017-06-741033. Epub 2017 Nov 8.

引用本文的文献

1
Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39.肿瘤中由Th1细胞转化而来的调节性T细胞通过CD39抑制癌症免疫。
J Exp Med. 2025 Apr 7;222(4). doi: 10.1084/jem.20240445. Epub 2025 Feb 5.
2
Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities.使用活化淋巴细胞联合其他抗癌方式治疗肺癌的前景。
Adv Respir Med. 2024 Dec 6;92(6):504-525. doi: 10.3390/arm92060045.
3
Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.新型 CCR8/CTLA-4 双特异性抗体的临床前开发用于癌症治疗，通过破坏 CD8 T 细胞上的 CTLA-4 信号传导并特异性耗尽肿瘤驻留的 Tregs。
Cancer Immunol Immunother. 2024 Aug 9;73(10):210. doi: 10.1007/s00262-024-03794-3.
4
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略
Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.
5
Immunologic tumor microenvironment modulators for turning cold tumors hot.免疫肿瘤微环境调节剂可使冷肿瘤变热。
Cancer Commun (Lond). 2024 May;44(5):521-553. doi: 10.1002/cac2.12539. Epub 2024 Mar 29.
6
Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy.点亮冷肿瘤微环境的“火”：提高癌症免疫治疗的一大挑战。
Cells. 2023 Jul 5;12(13):1787. doi: 10.3390/cells12131787.
7
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.肿瘤免疫治疗的治疗靶点和生物标志物：反应与无反应。
Signal Transduct Target Ther. 2022 Sep 19;7(1):331. doi: 10.1038/s41392-022-01136-2.
8
A Hot Topic: Cancer Immunotherapy and Natural Killer Cells.热门话题：癌症免疫疗法与自然杀伤细胞
Int J Mol Sci. 2022 Jan 12;23(2):797. doi: 10.3390/ijms23020797.
9
Comprehensive Analysis of Innate Immunophenotyping Based on Immune Score Predicting Immune Alterations and Prognosis in Breast Cancer Patients.基于免疫评分的固有免疫表型综合分析预测乳腺癌患者的免疫改变和预后。
Genes (Basel). 2021 Dec 29;13(1):88. doi: 10.3390/genes13010088.
10
Trial watch: intratumoral immunotherapy.试验观察：肿瘤内免疫疗法。
Oncoimmunology. 2021 Oct 15;10(1):1984677. doi: 10.1080/2162402X.2021.1984677. eCollection 2021.

本文引用的文献

1
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.首个免疫检查点抑制剂伊匹单抗治疗癌症的结构基础。
Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4223-E4232. doi: 10.1073/pnas.1617941114. Epub 2017 May 8.
2
Coinhibitory Pathways in Immunotherapy for Cancer.癌症免疫治疗中的共抑制途径。
Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25.
3
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.黑色素瘤患者体内非经典单核细胞在体外对调节性T细胞的依匹木单抗依赖性细胞介导的细胞毒性作用
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5. doi: 10.1073/pnas.1417320112. Epub 2015 Apr 27.
4
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.癌症治疗中的免疫检查点靶向治疗：迈向具有治愈潜力的联合策略。
Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030.
5
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.IgG2a 同种型的抗 CTLA-4 抗体通过减少肿瘤内调节性 T 细胞增强抗肿瘤活性。
Cancer Immunol Res. 2013 Jul;1(1):32-42. doi: 10.1158/2326-6066.CIR-13-0013. Epub 2013 Apr 7.
6
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.激活 Fcγ 受体有助于免疫调节受体靶向抗体的抗肿瘤活性。
J Exp Med. 2013 Aug 26;210(9):1685-93. doi: 10.1084/jem.20130573. Epub 2013 Jul 29.
7
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.Fc 依赖性耗竭肿瘤浸润调节性 T 细胞共同定义了抗 CTLA-4 治疗对黑色素瘤的疗效。
J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130579. Epub 2013 Jul 29.
8
Ipilimumab and its toxicities: a multidisciplinary approach.依匹木单抗及其毒性：一种多学科方法。
Oncologist. 2013 Jun;18(6):733-43. doi: 10.1634/theoncologist.2012-0483. Epub 2013 Jun 17.
9
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.在单一部位耗尽肿瘤特异性 Tregs 可消除播散性肿瘤。
J Clin Invest. 2013 Jun;123(6):2447-63. doi: 10.1172/JCI64859.
10
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.Fcγ 受体多态性在癌症中对单克隆抗体反应的作用的批判性评价。
J Hematol Oncol. 2013 Jan 4;6:1. doi: 10.1186/1756-8722-6-1.